key: cord-0872250-p4krye3n
authors: Comber, Sean D W; Upton, Mathew; Lewin, Shaun; Powell, Neil; Hutchinson, Thomas H
title: COVID-19, antibiotics and One Health: a UK environmental risk assessment
date: 2020-08-12
journal: J Antimicrob Chemother
DOI: 10.1093/jac/dkaa338
sha: 2e5767f0573aedc81b3d8e2203b3d21b26ba79f6
doc_id: 872250
cord_uid: p4krye3n

nan

Sir, There is growing interest in the role of secondary bacterial and fungal infections as a cause of increased morbidity and mortality in COVID-19 patients, 1 with reports of up to 95% of COVID-19 inpatients being prescribed antibiotics. 2 Concerns have been raised over the environmental implications of such a large-scale drug administration 3 and statements made about the potential impacts of COVID-19-related antibiotic prescription on antimicrobial resistance (AMR) and other toxicological effects on the environment. 4 The UK National Strategy aims for a world in which AMR is effectively contained, controlled and mitigated by 2040. 5 Taking a 'One Health' approach to effective stewardship in settings such as those being experienced in the current pandemic will be key to minimizing the negative impacts of antibiotic use. A large proportion of some drugs (and metabolites) are excreted by patients into wastewater treatment works (WwTW), leading to release of drug residues into effluent-receiving rivers and coastal waters. Environmental concentrations and impacts will be greatest where drugs are used in high volumes, pass through WwTW largely undegraded and are discharged into rivers with limited dilution.

Since 2006, the EMA has required risk assessments of human medicines to allow standardized quantification of the environmental impact of pharmaceuticals. Consequently, the pharmaceutical industry has developed a database to provide Predicted No Effect Concentrations as Minimum Inhibitory Concentrations (PNEC-MIC) for active ingredients that may select for AMR, or levels hazardous to fish and other environmental species (PNEC-ENV). 6 Combined with Predicted Environmental Concentrations (PEC), generated using monitoring and modelling data, a risk assessment may be carried out. Should the PEC of individual drugs exceed either the PNEC-MIC or PNEC-ENV, further investigations are required.

To examine the potential impact of antibiotic prescribing in COVID-19 patients in the UK, we have undertaken a risk assessment based on established principles. 7 Patient numbers were obtained for UK emergency hospitals set up temporarily around the country to receive COVID-19 patients, with one chosen for illustrative purposes, and details of WwTW capacity and river water dilution serving the emergency hospital and associated town were available from previous research. 8 Antibiotic excretion rates were obtained from the open literature. These data allowed estimation of antibiotic loads entering the WwTW, over and above the expected baseline (non-COVID-19) use for UK patients. 9 A freely available and validated wastewater process model (SimpleTreat 4.0) was used to predict removal rates, which allowed predictions of effluent concentrations for antibiotics of interest being discharged to surface waters. Based on known dilution estimates, a PEC:PNEC ratio was derived to provide a risk ratio.

We illustrate here data relevant to a single UK emergency hospital (Harrogate, with 500 beds; see Figure S1 , available as Supplementary data at JAC Online) in different COVID-19 scenarios, providing environmental assessments relevant to designing optimal drug use and waste management systems in a One Health context. NICE COVID-19 guidance was followed, which suggests that the first-line antibiotic should be doxycycline, with amoxicillin as second line. NICE guidelines for secondary care suggest doxycycline or a combination of clarithromycin and coamoxiclav. Clavulanic acid does not have a PNEC value, so data presented here are for the impact of amoxicillin alone. Use of antibiotics in COVID-19 patients in hospitals will lead to the release of drug residues into UK rivers or coastal waters from any WwTW ( Figure S1 ). Under pandemic scenarios, the use of antibiotics will obviously increase dramatically, thus increasing the overall burden on WwTW and potentially the receiving waters. Data available for the UK make it possible to carry out a risk assessment for site-specific areas. 10 To examine more focused regional impacts, we have calculated PEC data for the UK emergency hospital at Harrogate (Figure 1 ) based on modelling tools developed through the UK water industry-sponsored Chemical Investigation Programme and briefly described above. 7 We predict PEC:PNEC risk ratios of <1.0 for doxycycline and up to 5.70 for amoxicillin under two COVID-19 scenarios (all beds occupied and 70% or 95% of patients prescribed antibiotics, with all patients receiving either doxycycline or amoxicillin). The data for amoxicillin indicate a potential environmental concern for selection of AMR, but not toxicity to fish and other environmental organisms.

We have not modelled scenarios for hospitals where different proportions of patients receive one or other antibiotic, though in future this may inform best practice for minimizing selection for AMR or causing toxic environmental effects.

We recommend more extensive environmental assessments be undertaken for all antimicrobial medicines used during V C The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecom mons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com pandemics. This will facilitate development of a robust evidence base in order to guide antibiotic prescribing choices that are less likely to increase AMR 11 and have the least environmental impact, thus supporting the UK National Strategy. 5 Such information could also inform future decisions on the location of emergency hospitals and wider drug and waste management to ensure optimal patient and environmental outcomes during pandemics.

This research was carried out using internal funding.

None to declare. 

Co-infections: potentially lethal and unexplored in COVID-19

Science-based targets for antibiotics in receiving waters from pharmaceutical manufacturing operations

The removal of pharmaceuticals during wastewater treatment: can it be predicted accurately?

Active pharmaceutical ingredients entering the aquatic environment from wastewater treatment works: a cause for concern?

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)

Development of a chemical source apportionment decision support framework for catchment management

COVID-19 and the potential long-term impact on antimicrobial resistance